TrialJournal of gastroenterology2020

REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.

Tatsuya Yamashita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.